>>14568332 (PB) Electrical Device that “gives DNA vaccines the boost they need to work in humans” Receives $71M from U.S. Dept of Defense

According to the article, the company's name is Inovio, located in Blue Bell Pennyslvania.

Looked them up in the USAspending.gov database.

$88+ Million dollars for all FYs.

Inovio's largest funding occurred in 2015 when there was $44.1 Million dollars obligated for…. (Oh, Hello Dr. Fauci) "Electrocorporation" of HIV drugs funded by NIAID. The recipient company on the electroporation contract was VGX corporation, located in Plymouth Meeting, PA. and VGX has rec'd $24.3 million as a 'child' recipient of Inovio. Modification #3 of contract HHSN272200800063C updates funding and extends the base period of a subcontract to the University of Pennsylvania.

Fauci and Gates Fund Inovio research

Inovio to VGX

VGX to U of Penn

Decided that electroporation sounded generally like a sketchy idea, especially since the plan now is to mess with DNA, not just RNA.

Electroporation in the USAspending.gov database for all FYs = $69.7 Million

The disgusting part is that electroporation in the advanced search data shows 'electroporation cuvettes' being funded by Dept. of Vet. Affairs as far back as 2007. Have they been using Vets as test subjects??

https://www.usaspending.gov/recipient/29692abc-fc1e-93a6-af49-fa4b5107cdab-C/all

(electroporation) https://www.usaspending.gov/search/?hash=e0ffe02f412c892eeb9ea0c74cfeba6e

>>14569347 (me)

President of Inovio - member of International Vaccine Institute and Council of Korean Americans and Member of The Aspen Institute, Inc. and Member of Aspen Global Leadership Network.

Dr. Joseph Kim

Dr. Joseph Kim was appointed President and CEO of Inovio Pharmaceuticals in June 2009. Dr. Kim co-founded VGX Pharmaceuticals, a synthetic vaccine company, in 2000 to develop intellectual property related to immunotherapeutics licensed from the University of Pennsylvania. He led that company for nine years and combined VGX with Inovio Biomedical in 2009 to form Inovio Pharmaceuticals. Previously, Dr. Kim was a senior vaccine developer at Merck & Co. where he successfully led efforts in manufacturing and process development for several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim earned a Bachelor of Science degree in Chemical Engineering and Economics from the Massachusetts Institute of Technology (MIT), where he was a U.S. Senate Honors Scholar. He holds a PhD in Biochemical Engineering from the University of Pennsylvania and a Master of Business Administration degree in Finance from the Wharton School. Dr. Kim has published more than 100 peer-reviewed scientific papers, holds numerous patents and sits on several editorial boards and review panels.

https://archive.md/dSeo7

https://archive.md/Y8urM